PUBLISHER: DataM Intelligence | PRODUCT CODE: 1138378
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1138378
Ultra-Large Volume Wearable Injectors Market size was valued US$ 2.56 billion in 2021 and is estimated to reach US$ 5.94 billion by 2029, growing at a CAGR of 8.6% during the forecast period (2022-2029).
The ultra-large volume wearable injectors are the medical devices used to deliver the large volume of drugs to the patients through the subcutaneous administration route by adhering to the body over a longer period of time. These devices allow the self-administration of the high-volume, high-viscosity drugs in a non-clinical setting.
The global ultra-large volume wearable injectors market is growing due to several factors such as the increasing prevalence of chronic diseases with the rising aging population as chronic diseases are the leading cause of mortality and morbidity worldwide and various novel technological advancements.
Providing convenient delivery in healthcare settings and new developments are expected to drive market growth.
The market growth is driven by the increasing prevalence of chronic diseases with the rising aging population as chronic diseases are the leading cause of mortality and morbidity worldwide. According to the World Health Organization (WHO), the burden of chronic diseases is expected to reach 57% by 2020. Almost half of the deaths occurred due to cardiovascular diseases, obesity, and diabetes. The existing treatment available in the market for chronic diseases includes parenteral administration, frequent dosing, involve repeated hospital visits. This existing treatment increases the risk of developing microbial infection and needlestick injuries. It also impacts medication adherence. Hence, many companies are focusing on the development of advanced therapeutic delivery solutions for overcoming adverse events. This has led to the introduction of self-injected delivery solutions for drug administration beyond the clinical setting. This has resulted in reducing healthcare costs and improving drug adherence.
The market growth is influenced by the rising demand for ultra-large volume wearable injectors due to their advantages of providing convenient delivery in healthcare settings. There is growing adoption of ultra-large volume wearable injectors compared to the traditional infusion pump as ultra-large volume wearable injectors provide the larger volume drugs with higher viscosity within the 2 - 30 minutes. In contrast, the infusion pump performs drug infusions over hours or days. Moreover, the ultra-large volume wearable injectors are easy to use as these ultra-large volume wearable injectors have low injection frequency and need to wear the device.
There is increasing research and development activities for the ultra-large volume wearable injectors. The novel ultra-large volume wearable injectors expected approvals should stimulate the market growth over the forecasted period. For instance, Becton, Dickinson, and Company are developing an ultra-large volume wearable injector, i.e., BD Libertas, for the self-administration of large volume and high viscosity drugs subcutaneously for the treatment of various chronic diseases over longer periods of time. It is a pre-filled, pre-assembled injector is designed to prioritize safety, convenience, and usability, while delivering high-value drug treatments in the comfort of an in-home environment.
The subject is developing the Subject Wearable Bolus Injector (WBI) that provides a longer delivery time for larger, viscous doses than auto-injectors. It allows the self-administration of large doses over a pre-defined delivery period to avoid injection site leakage, local intolerability, injection pain, etc. It injects the drugs with high viscosities and accommodates high dose volumes (1-10 ml). It would provide the Simple (one button) activation and noiseless operation. It automatically inserts the needle at activation and retracts the needle after completion.
High cost of these injectors is expected to hamper the market growth.
The global ultra large volume wearable injectors market can be restrained because of high cost associated with these wearable injectors and lack of reimbursement in some developing countries can also affect the growth of market.
The global ultra-large volume wearable injectors market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis.
Product type segment is expected to hold the largest market share in global ultra-large volume wearable injectors market
The ultra-large volume wearable injectors market is segmented based on product type as electromechanical wearable injectors, mechanical wearable injectors, etc. The electromechanical wearable injectors segment accounts for the highest market share. The electromechanical ultra-large volume wearable injectors deliver the drug by building the pressure with an electrical motor's help. The electromechanical devices deliver medication at a constant delivery instead of tissue back-pressure. There is an increase in the number of companies developing electromechanical ultra-large volume wearable injectors. For instance, YpsoDose is a single-use ultra-large volume wearable injector under the development by Ypsomed Holding AG. It is an electromechanical pre-filled and pre-assembled patch device for 10 ml glass cartridges. It is patched directly to the skin with an integrated pre-filled drug reservoir, sterile fluid path, and needle system. It has a unique programmable electromechanical drive system for a range of viscosities and fills volumes. It is effective in performing the needle insertion, injection, end of injection feedback, and needle safety steps automatically. It is comprised of customizable device housing shells to provide customer-specific device designs.
The mechanical wearable injectors segment is expected to have positive market growth due to the mechanical ultra-large volume wearable injectors' ability to reduce risk and increase reliability. The mechanical wearable injectors provide more comfortable injections than the electromechanical wearable injectors as these injectors are responsive to tissue back-pressure.
Further, the market is also classified based on diabetes, auto-immune disease, blood disorders, cancer, etc. The diabetes segment accounts for the highest market share. The prevalence of diabetes is increasing with the rise in the aging population. According to the International Diabetes Federation (IDF), approximately 463 million adults of age-group 20-79 have Diabetes worldwide and are expected to increase and reach up to 700 million by 2045. More than 1.1 million children and adolescents are living with type 1 diabetes worldwide. Around 374 million people are at increased risk of developing type 2 diabetes. The introduction of the ultra-large volume wearable injectors overcome the limitations of the existing treatment for diabetes, including the difficulty in tracking the frequency of doses, leading to two missed doses or even double doses, fear of needles, and painful injections. The ultra-large volume wearable injectors allow the tracking and sharing of the injection data to improve adherence and therapy outcomes among patients with diabetes. These wearable injectors provide comfort, convenience, and discreetness in improving the patient's quality of life.
North America region holds the largest market share in the global ultra-large volume wearable injectors market
By region, the ultra-large volume wearable injectors market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the ultra-large volume wearable injectors market due to the large number of biologics suited for delivery via self-administered injection that is approved or under development to treat chronic conditions require frequent dosing. The high prevalence of chronic disease shall stimulate market growth. According to the Centers for Disease Control and Prevention (CDC), around 6 in 10 people are affected by one chronic disease. Approximately 4 in 10 people are suffering from two or more chronic diseases. The United States is expected to have the highest market share. The ease of availability of ultra-large volume wearable injectors and high healthcare expenditure to improve healthcare facilities will fuel market growth. The North America region is expected to maintain its dominant position over the forecasted period.
The Asia Pacific region is expected to have positive market growth due to increasing awareness regarding the advantages of ultra-large volume wearable injectors for drug administration. Patient self-administration of subcutaneous injections is expected to save approximately 30% to 70% of costs. Thus, it provides lucrative opportunities for market players. The rising research and development activities for ultra-large volume wearable injectors especially in China, Australia, and Japan, will positively impact the market. The demand for ultra-large volume wearable injectors is expected to increase with the increasing per-capita healthcare, domestic income, purchasing power, and healthcare expenditure over the forecasted period.
The ultra-large volume wearable injectors market is highly competitive with the presence of several international and local markets. Product development, technological advancement, and opportunities intensify the market competition. Becton, Dickinson and Company, Ypsomed Holding AG, Enable Injections, Inc., Medtronic Plc., Amgen Inc., and Sensile Medical AG (Gerresheimer AG) are the leading market players with significant market share.
Companies have increased their research and development activities for ultra-large volume wearable injectors. For instance, in February 2020, Becton, Dickinson, and Company had completed the 50-subject human clinical trial with the BD Libertas Wearable Injector. This study was conducted to examine the performance of the 5 mL BD Libertas device in human subjects, including tissue effects, skin reactivity, and patient acceptance. In March 2019, Becton, Dickinson, and Company had won the Good Design Award for the BD Libertas Wearable Injector. Moreover, the company had also received the iF Award for its BD Libertas Wearable Injector.
The companies enter into collaborations, mergers, strategic partnerships, and acquisitions to increase the demand for ultra-large volume wearable injectors market and their expansion across the globe.
Overview: BD is an American medical technology multinational company. It manufactures medical devices, reagents and instruments system. Was founded 1897 and headquartered in New Jersey, U.S.
BD Libertas Wearable Injectors: These BD Wearable Injector are developed as drug delivery system that is pre-fillable for different products. It is an injection system that delivers complex biologics around 2-5 ml or 5-10 ml that too in clinics or in home.
Key Developments: In May 2022, BD and Babson expanded their Partnership for various technological advances in diagnostic blood collection in new care settings.
The global ultra-large volume wearable injectors market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
LIST NOT EXHAUSTIVE